NASDAQ:AKER - Akers Biosciences Stock Price, Price Target & More

$0.5365 -0.01 (-1.83 %)
(As of 04/24/2018 08:53 AM ET)
Previous Close$0.5501
Today's Range$0.5250 - $0.5550
52-Week Range$0.12 - $2.10
Volume3.33 million shs
Average Volume16.60 million shs
Market Capitalization$45.09 million
P/E RatioN/A
Dividend YieldN/A
Beta-1.07

About Akers Biosciences (NASDAQ:AKER)

Akers Biosciences, Inc., together with its subsidiaries, develops, manufactures, and supplies rapid screening and testing products designed to deliver healthcare information to healthcare providers and consumers in the United States and internationally. The company's marketed products include BreathScan, a disposable breath alcohol detector; BreathScan PRO, a quantitative breath alcohol detection system; METRON, a disposable breath ketone device to monitor ketosis; and BreathScan Lync, a non-invasive, quantitative measurement of biological markers for health and wellness. Its marketed products also include PIFA Heparin/PF4 and PIFA PLUSS PF4 rapid tests for Heparin/PF4 antibodies to detect an allergy to the used blood thinner, Heparin; seraSTAT, a rapid blood cell separator; Tri-Cholesterol ?Check', a rapid test for total and high density lipoprotein cholesterol and estimates low density lipo protein; and BreathScan OxiCHek, a breath test for oxidative stress using the Lync reader and digital app. The company's pipeline products comprise Breath Diabetic Ketoacidosis, a disposable breath ketone device for diabetic monitoring; Breath PulmoHealth ?Check', a suite of breath tests for biomarkers indicating asthma, chronic obstructive pulmonary disease, and lung cancer; PIFA PLUSS Chlamydia, a rapid test for sexually transmitted diseases; and BreathScan KetoChek, a breath test for ketosis using the Lync reader and digital app. Akers Biosciences, Inc. was founded in 1989 and is headquartered in Thorofare, New Jersey.

Receive AKER News and Ratings via Email

Sign-up to receive the latest news and ratings for AKER and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AKER
CUSIPN/A
Phone856-848-2116

Debt

Debt-to-Equity RatioN/A
Current Ratio5.27%
Quick Ratio4.23%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$3.93 million
Price / Sales11.19
Cash FlowN/A
Price / CashN/A
Book Value$0.17 per share
Price / Book3.16

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-5,800,000.00
Net Margins-147.74%
Return on Equity-104.85%
Return on Assets-77.26%

Miscellaneous

Employees32
Outstanding Shares81,970,000

How to Become a New Pot Stock Millionaire

Akers Biosciences (NASDAQ:AKER) Frequently Asked Questions

What is Akers Biosciences' stock symbol?

Akers Biosciences trades on the NASDAQ under the ticker symbol "AKER."

How were Akers Biosciences' earnings last quarter?

Akers Biosciences (NASDAQ:AKER) issued its earnings results on Wednesday, November, 15th. The medical instruments supplier reported ($0.13) EPS for the quarter. The medical instruments supplier earned $0.68 million during the quarter. Akers Biosciences had a negative return on equity of 104.85% and a negative net margin of 147.74%. View Akers Biosciences' Earnings History.

When is Akers Biosciences' next earnings date?

Akers Biosciences is scheduled to release their next quarterly earnings announcement on Tuesday, May, 15th 2018. View Earnings Estimates for Akers Biosciences.

Who are some of Akers Biosciences' key competitors?

Who are Akers Biosciences' key executives?

Akers Biosciences' management team includes the folowing people:
  • Dr. Raymond F. Akers Jr., Co-Founder, Exec. Chairman, Chief Scientific Director & Sec. (Age 60)
  • Mr. John J. Gormally, CEO & Director (Age 62)
  • Mr. Gary M. Rauch, VP of Fin., Treasurer, CFO & Principal Accounting Officer (Age 62)
  • Mr. Douglas Carrara, Sr. VP of Global Marketing & Commercial Operations
  • Ms. Pamela E. Hibler, VP of Sales & Distribution

Has Akers Biosciences been receiving favorable news coverage?

News coverage about AKER stock has trended somewhat positive on Tuesday, according to Accern Sentiment. The research firm rates the sentiment of press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Akers Biosciences earned a media sentiment score of 0.13 on Accern's scale. They also gave news articles about the medical instruments supplier an impact score of 49.30 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

How do I buy shares of Akers Biosciences?

Shares of AKER can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Akers Biosciences' stock price today?

One share of AKER stock can currently be purchased for approximately $0.5365.

How big of a company is Akers Biosciences?

Akers Biosciences has a market capitalization of $45.09 million and generates $3.93 million in revenue each year. Akers Biosciences employs 32 workers across the globe.

How can I contact Akers Biosciences?

Akers Biosciences' mailing address is 201 GROVE RD, THOROFARE NJ, 08086. The medical instruments supplier can be reached via phone at 856-848-2116 or via email at [email protected]


MarketBeat Community Rating for Akers Biosciences (AKER)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  65 (Vote Outperform)
Underperform Votes:  81 (Vote Underperform)
Total Votes:  146
MarketBeat's community ratings are surveys of what our community members think about Akers Biosciences and other stocks. Vote "Outperform" if you believe AKER will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKER will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Akers Biosciences (NASDAQ:AKER) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
(Data available from 4/24/2016 forward)

Earnings

Akers Biosciences (NASDAQ:AKER) Earnings History and Estimates Chart

Earnings by Quarter for Akers Biosciences (NASDAQ:AKER)

Akers Biosciences (NASDAQ AKER) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/14/2018N/AView Earnings Details
11/15/2017n/a($0.13)$0.68 millionViewN/AView Earnings Details
8/14/20176/30/2017($0.04)($0.08)$1.20 millionViewN/AView Earnings Details
5/16/20173/31/2017($0.19)$0.67 millionViewN/AView Earnings Details
4/11/2017Q4 2016($0.20)$0.65 millionViewN/AView Earnings Details
11/14/2016Q316$0.04$0.06$0.61 millionViewN/AView Earnings Details
8/11/2016Q216($0.19)$0.96 millionViewListenView Earnings Details
5/12/2016Q1 2016($0.28)$0.74 millionViewN/AView Earnings Details
3/30/2016Q4 2015($0.69)$0.47 millionViewN/AView Earnings Details
11/13/2015Q315($0.36)$0.17 millionViewListenView Earnings Details
8/18/2015Q215($0.41)$1.35 million$0.97 millionViewListenView Earnings Details
5/14/2015Q115($0.10)($0.26)$2.00 million$0.51 millionViewListenView Earnings Details
3/23/2015Q4 2014($0.19)$1.45 millionViewN/AView Earnings Details
11/13/2014Q314($0.17)($0.23)$1.40 million$453.30 millionViewN/AView Earnings Details
8/12/2014Q2 2014($0.16)($0.10)$1.35 millionViewN/AView Earnings Details
5/14/2014Q1 2014($0.14)$1.17 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Akers Biosciences (NASDAQ:AKER) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Akers Biosciences (NASDAQ AKER) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 8.93%
Institutional Ownership Percentage: 3.54%
Insider Trading History for Akers Biosciences (NASDAQ:AKER)

Akers Biosciences (NASDAQ AKER) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/24/2016John J GormallyCEOBuy2,500$2.23$5,575.0069View SEC Filing  
1/5/2016Raymond Francis Akers JrChairmanBuy2,100$1.34$2,814.00View SEC Filing  
12/11/2015Gary M RauchVPBuy3,500$1.50$5,250.005,000View SEC Filing  
8/22/2014Gary M RauchVPBuy1,020$3.15$3,213.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Akers Biosciences (NASDAQ AKER) News Headlines

Source:
DateHeadline
BRIEF-Akers Biosciences Expands Outsourced US Distribution Capabilities For Heparin PF4 Rapid TestBRIEF-Akers Biosciences Expands Outsourced US Distribution Capabilities For Heparin PF4 Rapid Test
www.reuters.com - April 14 at 8:29 AM
Akers Biosciences To Raise USD750,000 Following Warrants Exercise (ALLISS)Akers Biosciences To Raise USD750,000 Following Warrants Exercise (ALLISS)
www.morningstar.co.uk - April 13 at 5:26 PM
BRIEF-Akers Biosciences Expands Outsourced U.S. Distribution Capabilities For Heparin PF4 Rapid TestBRIEF-Akers Biosciences Expands Outsourced U.S. Distribution Capabilities For Heparin PF4 Rapid Test
www.reuters.com - April 12 at 8:48 AM
Akers Bio beefs up U.S. distribution for Heparin PF4 rapid test; shares up 7% premarketAkers Bio beefs up U.S. distribution for Heparin PF4 rapid test; shares up 7% premarket
seekingalpha.com - April 12 at 8:48 AM
Akers Biosciences Expands Outsourced US Distribution Capabilities for Heparin PF4 Rapid TestAkers Biosciences Expands Outsourced US Distribution Capabilities for Heparin PF4 Rapid Test
finance.yahoo.com - April 12 at 8:48 AM
Form 4/A Akers Biosciences, Inc. For: Oct 17 Filed by: Gormally John JForm 4/A Akers Biosciences, Inc. For: Oct 17 Filed by: Gormally John J
www.streetinsider.com - April 11 at 8:37 AM
Akers Biosciences Raises USD814,444 After Warrants Exercise (ALLISS)Akers Biosciences Raises USD814,444 After Warrants Exercise (ALLISS)
www.morningstar.co.uk - April 6 at 5:37 PM
Akers Biosciences (AKER) Reports FY17 Revenue of $3.93MAkers Biosciences (AKER) Reports FY17 Revenue of $3.93M
www.streetinsider.com - April 4 at 8:28 AM
Akers Biosciences 2017 Revenue Rises But Loss Widens On Higher CostsAkers Biosciences 2017 Revenue Rises But Loss Widens On Higher Costs
www.lse.co.uk - April 3 at 5:29 PM
Akers Biosciences (AKER) CEO John Gormally on Q4 2017 Results - Earnings Call TranscriptAkers Biosciences (AKER) CEO John Gormally on Q4 2017 Results - Earnings Call Transcript
seekingalpha.com - April 3 at 5:29 PM
Akers Biosciences down 15% premarket on FY 2017 resultsAkers Biosciences down 15% premarket on FY 2017 results
seekingalpha.com - April 3 at 8:30 AM
Akers Biosciences Inks US Distribution Pact With Diagnostica Stago (ALLISS)Akers Biosciences Inks US Distribution Pact With Diagnostica Stago (ALLISS)
www.morningstar.co.uk - March 26 at 5:12 PM
Akers Biosciences signs US distribution agreement with Diagnostica Stago; shares ahead 14% premarketAkers Biosciences signs US distribution agreement with Diagnostica Stago; shares ahead 14% premarket
seekingalpha.com - March 26 at 5:12 PM
Akers Bio signs 3-year distribution deal with Diagnostica StagoAkers Bio signs 3-year distribution deal with Diagnostica Stago
finance.yahoo.com - March 26 at 5:12 PM
Akers Biosciences (AKER) Enters US Distribution Agreement with Diagnostica StagoAkers Biosciences (AKER) Enters US Distribution Agreement with Diagnostica Stago
www.streetinsider.com - March 26 at 8:29 AM
BRIEF-Akers Biosciences Signs Distribution Agreement With Diagnostica StagoBRIEF-Akers Biosciences Signs Distribution Agreement With Diagnostica Stago
www.reuters.com - March 26 at 8:29 AM
Akers Biosciences Signs US Distribution Agreement with Diagnostica StagoAkers Biosciences Signs US Distribution Agreement with Diagnostica Stago
finance.yahoo.com - March 26 at 8:29 AM
Consolidated Research: 2018 Summary Expectations for Brixmor Property Group, First Majestic Silver, Barclays, Akers Biosciences, Precision Drilling, and NBT — Fundamental Analysis, Key Performance IndicationsConsolidated Research: 2018 Summary Expectations for Brixmor Property Group, First Majestic Silver, Barclays, Akers Biosciences, Precision Drilling, and NBT — Fundamental Analysis, Key Performance Indications
finance.yahoo.com - March 26 at 8:29 AM
Akers Biosciences (AKER) Set to Announce Quarterly Earnings on ThursdayAkers Biosciences (AKER) Set to Announce Quarterly Earnings on Thursday
www.americanbankingnews.com - March 22 at 1:34 AM
Akers Biosciences Nets USD49,000 From Warrants Exercise (ALLISS)Akers Biosciences Nets USD49,000 From Warrants Exercise (ALLISS)
www.morningstar.co.uk - March 16 at 6:24 PM
Akers Biosciences Announces Conference Call to Discuss Fiscal Year 2017 Earnings - GlobeNewswire (press release)Akers Biosciences Announces Conference Call to Discuss Fiscal Year 2017 Earnings - GlobeNewswire (press release)
globenewswire.com - March 16 at 8:27 AM
Akers Biosciences Issues 1.5 Million Shares After Warrants Exercise (ALLISS)Akers Biosciences Issues 1.5 Million Shares After Warrants Exercise (ALLISS)
www.morningstar.co.uk - March 2 at 6:03 PM
Did Akers Biosciences Inc’s (NASDAQ:AKER) Earnings Growth Outperform The Industry?Did Akers Biosciences Inc’s (NASDAQ:AKER) Earnings Growth Outperform The Industry?
finance.yahoo.com - March 1 at 8:20 AM
Akers Biosciences Shares Bouncing Back, New Self Diagnostic Products Being DevelopedAkers Biosciences Shares Bouncing Back, New Self Diagnostic Products Being Developed
finance.yahoo.com - February 26 at 8:24 AM
Akers Biosciences Receives USD882,281 After Share Warrant Exercise (ALLISS)Akers Biosciences Receives USD882,281 After Share Warrant Exercise (ALLISS)
www.morningstar.co.uk - February 16 at 5:14 PM
Akers Biosciences Inc (AKER) Sees Large Growth in Short InterestAkers Biosciences Inc (AKER) Sees Large Growth in Short Interest
www.americanbankingnews.com - February 9 at 5:26 PM
Akers Biosciences Issues 11.4 Million Shares After Warrants Exercise (ALLISS)Akers Biosciences Issues 11.4 Million Shares After Warrants Exercise (ALLISS)
www.morningstar.co.uk - February 9 at 4:01 PM
Akers Biosciences Nets USD95,625 From Warrant Exercise (ALLISS)Akers Biosciences Nets USD95,625 From Warrant Exercise (ALLISS)
www.morningstar.co.uk - February 2 at 3:52 PM
Akers Biosciences Issues 2.8 Million Shares After Warrants Exercise (ALLISS)Akers Biosciences Issues 2.8 Million Shares After Warrants Exercise (ALLISS)
www.morningstar.co.uk - January 26 at 9:50 AM
Short Interest in Akers Biosciences Inc (AKER) Declines By 63.3%Short Interest in Akers Biosciences Inc (AKER) Declines By 63.3%
www.americanbankingnews.com - January 14 at 3:40 AM
Akers Biosciences Gets Conversion Notice Worth 9.4 Million Shares (ALLISS)Akers Biosciences Gets Conversion Notice Worth 9.4 Million Shares (ALLISS)
www.morningstar.co.uk - January 13 at 3:50 PM
2 Healthcare Testing & Diagnostic Stocks Taking Center Stage Ahead of JP Morgan Conference2 Healthcare Testing & Diagnostic Stocks Taking Center Stage Ahead of JP Morgan Conference
finance.yahoo.com - January 9 at 3:55 PM
Akers Biosciences, Inc. :AKER-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017Akers Biosciences, Inc. :AKER-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017
finance.yahoo.com - December 25 at 4:41 PM
BRIEF-Alpha Capital Anstalt Reports 9.9 Pct Passive Stake In Akers BiosciencesBRIEF-Alpha Capital Anstalt Reports 9.9 Pct Passive Stake In Akers Biosciences
www.reuters.com - December 22 at 5:27 PM
Akers Biosciences To Raise USD6.0 Million In Open Offer (ALLISS)Akers Biosciences To Raise USD6.0 Million In Open Offer (ALLISS)
www.morningstar.co.uk - December 19 at 3:53 PM
Here’s Why Akers Biosciences Inc (AKER) Shares Are CollapsingHere’s Why Akers Biosciences Inc (AKER) Shares Are Collapsing
finance.yahoo.com - December 19 at 3:53 PM
ValuEngine Upgrades Akers Biosciences (AKER) to HoldValuEngine Upgrades Akers Biosciences (AKER) to Hold
www.americanbankingnews.com - December 4 at 12:22 AM
What Is Akers Biosciences Inc’s (AIM:AKR) Share Price Doing?What Is Akers Biosciences Inc’s (AIM:AKR) Share Price Doing?
finance.yahoo.com - November 28 at 10:40 AM
Akers Biosciences Inc (AKER) Issues  Earnings ResultsAkers Biosciences Inc (AKER) Issues Earnings Results
www.americanbankingnews.com - November 16 at 9:16 AM
Akers Biosciences UK Distributor Secures New Channel For Rapid Alcohol BreathalyzerAkers Biosciences' UK Distributor Secures New Channel For Rapid Alcohol Breathalyzer
www.thestreet.com - November 14 at 9:11 PM
BRIEF-Akers Biosciences - Accutest Solutions secured new channel partner for salesBRIEF-Akers Biosciences - Accutest Solutions secured new channel partner for sales
www.reuters.com - November 14 at 4:10 PM
Akers Biosciences’ UK Distributor Secures New Channel for Rapid Alcohol BreathalyzerAkers Biosciences’ UK Distributor Secures New Channel for Rapid Alcohol Breathalyzer
finance.yahoo.com - November 14 at 4:10 PM
Akers Biosciences Announces Conference Call to Discuss Q3 2017 EarningsAkers Biosciences Announces Conference Call to Discuss Q3 2017 Earnings
finance.yahoo.com - November 14 at 2:51 AM
Have Investors Already Priced In Akers Biosciences Inc’s (AKER) Growth?Have Investors Already Priced In Akers Biosciences Inc’s (AKER) Growth?
finance.yahoo.com - November 14 at 2:51 AM
Akers Biosciences Inc (AKER) to Release Earnings on MondayAkers Biosciences Inc (AKER) to Release Earnings on Monday
www.americanbankingnews.com - November 6 at 5:22 AM
Global Cholesterol Testing Market, 2024Global Cholesterol Testing Market, 2024
www.finanznachrichten.de - October 21 at 8:33 PM
Akers Biosciences Gets $387,000 From Exercise Of Warrants (ALLISS)Akers Biosciences Gets $387,000 From Exercise Of Warrants (ALLISS)
www.morningstar.co.uk - October 13 at 3:37 PM
Today’s Research Reports on Trending Tickers: Halozyme Therapeutics and Akers BiosciencesToday’s Research Reports on Trending Tickers: Halozyme Therapeutics and Akers Biosciences
finance.yahoo.com - October 13 at 3:37 PM
Akers Biosciences, Inc. :AKER-US: Earnings Analysis: Q2, 2017 By the Numbers : September 7, 2017Akers Biosciences, Inc. :AKER-US: Earnings Analysis: Q2, 2017 By the Numbers : September 7, 2017
finance.yahoo.com - September 7 at 3:40 PM
Akers Biosciences Interim Loss Narrows As Allergy Test Sales GrowAkers Biosciences Interim Loss Narrows As Allergy Test Sales Grow
www.morningstar.co.uk - August 15 at 4:43 PM

SEC Filings

Akers Biosciences (NASDAQ:AKER) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Akers Biosciences (NASDAQ:AKER) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Akers Biosciences (NASDAQ AKER) Stock Chart for Tuesday, April, 24, 2018

Loading chart…

This page was last updated on 4/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.